Envestnet Asset Management Inc. Has $16.79 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Envestnet Asset Management Inc. cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 19.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 271,764 shares of the medical equipment provider's stock after selling 67,520 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.12% of Hologic worth $16,787,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. EverSource Wealth Advisors LLC raised its stake in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares during the period. Commonwealth Equity Services LLC raised its stake in Hologic by 1.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 61,958 shares of the medical equipment provider's stock worth $4,467,000 after buying an additional 735 shares during the period. Corient Private Wealth LLC raised its stake in Hologic by 2.9% during the 4th quarter. Corient Private Wealth LLC now owns 53,306 shares of the medical equipment provider's stock worth $3,843,000 after buying an additional 1,518 shares during the period. Cibc World Markets Corp raised its stake in Hologic by 16.1% during the 4th quarter. Cibc World Markets Corp now owns 36,676 shares of the medical equipment provider's stock worth $2,644,000 after buying an additional 5,075 shares during the period. Finally, Signaturefd LLC raised its stake in shares of Hologic by 34.5% in the fourth quarter. Signaturefd LLC now owns 2,940 shares of the medical equipment provider's stock worth $212,000 after purchasing an additional 754 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Stock Up 0.3%

HOLX opened at $64.02 on Friday. The company has a market cap of $14.27 billion, a P/E ratio of 27.01, a P/E/G ratio of 2.34 and a beta of 0.55. The business's 50-day moving average price is $62.31 and its 200-day moving average price is $63.30. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the business earned $1.03 EPS. Hologic's revenue was down 1.2% compared to the same quarter last year. On average, equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Insiders Place Their Bets

In other news, Director Martin D. Madaus acquired 5,445 shares of the business's stock in a transaction on Wednesday, May 7th. The shares were acquired at an average cost of $55.24 per share, with a total value of $300,781.80. Following the transaction, the director owned 5,445 shares in the company, valued at $300,781.80. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.88% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on HOLX shares. Stephens lowered their price objective on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. Evercore ISI increased their price target on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Royal Bank Of Canada decreased their price target on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and increased their price target for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. Finally, Mizuho increased their price target on Hologic from $65.00 to $70.00 and gave the company an "outperform" rating in a research report on Wednesday. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Hologic presently has a consensus rating of "Hold" and an average price target of $77.33.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.